Shots:

• The P-III INBUILD trial involves assessing of OFEV vs PBO in patients with chronic fibrosing interstitial lung disease (ILDs) with signs of progression for 52 wks.
• P-III INBUILD study results: met its 1EPs- slowed lung function decline by 57%- adjusted annual rate of decline in FVC @52 wks. (-80.8 mL/year vs -187.8 mL/year). Ofev showed consistent effect on lung function decline in patients with UIP like fibrotic pattern and those with other fibrotic patterns on HRCT- consistent safety profile as found in IPF and SSc-ILD patients
• Ofev (nintedanib) is a tyrosine kinase inhibitor approved in 70+ countries including the US- EU and Japan for the treatment of patients living with idiopathic pulmonary fibrosis (IPF)   

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Twitter